Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC) (Businesswire) - Oct 19, 2023 - "Hummingbird Bioscience...and Endeavor BioMedicines...announced that Endeavor has acquired exclusive worldwide rights to Hummingbird Bio's antibody-drug conjugate (ADC), HMBD-501. The license agreement provides Endeavor with exclusive rights to HMBD-501, a next-generation HER3-targeted ADC with an exatecan payload that has been optimized for safety and efficacy. Under the terms of the license, Hummingbird Bio will be eligible to receive upfront and milestone payments up to $430 million, plus royalties on net sales....Investigational New Drug (IND) application planned in first half of 2024."
IND • Licensing / partnership • Oncology
|